![Christopher Ogden](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 430 332 $ in data 31/08/2026
Christopher Ogden is currently Chief Financial Officer, Secretary & Senior VP at CytomX Therapeutics, Inc. since 2021.
Former positions include Chief Financial Officer-Diabetes Division at Eli Lilly & Co. and Chief Financial Officer & Treasurer at Lilly del Caribe, Inc. Education includes an undergraduate degree from Wabash College and an MBA from Harvard Business School.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 15/06/2026 | 128.075 ( 0,08% ) | 430 332 $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Direttore Finanziario/CFO | 21/09/2022 |
| Società | Posizione | Fine |
|---|---|---|
Lilly del Caribe, Inc.
 Lilly del Caribe, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Direttore Finanziario/CFO | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Wabash College
 Wabash College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lilly del Caribe, Inc.
Lilly del Caribe, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics, Inc.
 CytomX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
